| Recruiting | Dose-Escalation Study of Artesunate Patients With IPF NCT05988463 | Joseph C. Wu | Phase 1 |
| Not Yet Recruiting | Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis NCT07520110 | University of Massachusetts, Worcester | Phase 3 |
| Not Yet Recruiting | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonar NCT07516951 | Chiesi Farmaceutici S.p.A. | Phase 2 |
| Not Yet Recruiting | OPEN-IPF: Observational Prediction modEl for cliNical Outcomes in Idiopathic Pulmonary Fibrosis NCT07404423 | University of Modena and Reggio Emilia | — |
| Recruiting | A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1 NCT06241560 | Boehringer Ingelheim | Phase 2 |
| Not Yet Recruiting | A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in NCT07454291 | Endeavor Biomedicines, Inc. | Phase 1 |
| Recruiting | Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis NCT07299695 | Argyrios Tzouvelekis | Phase 3 |
| Recruiting | Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathi NCT07230288 | AbbVie | Phase 2 |
| Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fib NCT07284459 | Contineum Therapeutics | Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korea NCT07407543 | siRNAgen Therapeutics Inc. | Phase 1 |
| Recruiting | A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibro NCT07036523 | Boehringer Ingelheim | Phase 2 |
| Recruiting | A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmaco NCT07225296 | Genosco Inc. | Phase 1 |
| Recruiting | Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis NCT06567717 | Cedars-Sinai Medical Center | Phase 2 |
| Recruiting | NAL ER IPF Respiratory Function and Safety Study NCT07036029 | Trevi Therapeutics | Phase 1 |
| Recruiting | Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease NCT06714123 | Vejle Hospital | Phase 2 |
| Not Yet Recruiting | Daoyin Technique for Improving Exercise Endurance in IPF NCT07019714 | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | N/A |
| Recruiting | A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis NCT06736990 | Calluna Pharma AS | Phase 2 |
| Recruiting | Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF) NCT07312305 | University of Milan | — |
| Recruiting | H01 in Adults With Interstitial Lung Disease (The SOLIS Study) NCT06325696 | National Institute of Environmental Health Sciences (NIEHS) | Phase 2 |
| Recruiting | WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) NCT06967805 | Mediar Therapeutics | Phase 2 |
| Recruiting | Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis NCT06853145 | University of Virginia | EARLY_Phase 1 |
| Active Not Recruiting | Evaluating the Diagnostic Performance of (HRCT) in IPD Fibrosis in Suspected Cases NCT07048652 | Superior University | — |
| Recruiting | SB17170 Phase 2 Trial in IPF Patients NCT06747923 | SPARK Biopharma | Phase 2 |
| Completed | Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis NCT06764862 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF NCT06683612 | Contineum Therapeutics | Phase 1 |
| Not Yet Recruiting | Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis NCT06668051 | Hacettepe University | — |
| Active Not Recruiting | A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) NCT06422884 | Endeavor Biomedicines, Inc. | Phase 2 |
| Completed | Real-life-persistence to Antifibrotic Treatments NCT06485635 | Boehringer Ingelheim | — |
| Completed | A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participan NCT06625489 | GlaxoSmithKline | Phase 1 |
| Completed | Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting an NCT06569381 | Overseas Pharmaceuticals, Ltd. | Phase 1 |
| Completed | A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) NCT06335303 | Boehringer Ingelheim | Phase 2 |
| Not Yet Recruiting | Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF NCT06488638 | University Hospital Southampton NHS Foundation Trust | N/A |
| Not Yet Recruiting | Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis NCT06521125 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Terminated | A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive NCT06360094 | Boehringer Ingelheim | Phase 2 |
| Recruiting | Skeletal Muscle Function in Interstitial Lung Disease NCT03800017 | University of British Columbia | N/A |
| Enrolling By Invitation | Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis NCT06629623 | Chu Hongling | — |
| Completed | A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Wh NCT06200714 | Boehringer Ingelheim | — |
| Recruiting | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers NCT06482190 | Shenzhen Resproly Biopharmaceutical Co., Ltd | Phase 1 |
| Recruiting | The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis NCT06323876 | University of Virginia | — |
| Recruiting | Ongoing Monitoring of Vital Signs in Patients With Idiopathic Pulmonary Fibrosis Before and After Acute Exacer NCT06445686 | Biosency | — |
| Recruiting | A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Pa NCT06238622 | Boehringer Ingelheim | Phase 3 |
| Completed | Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF NCT06331624 | GRI Bio Operations, Inc. | Phase 2 |
| Completed | Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healt NCT06588517 | Overseas Pharmaceuticals, Ltd. | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis ( NCT06317285 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-I NCT05983471 | Melius Pharma AB | Phase 2 |
| Completed | Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect NCT06265532 | Hal Chapman | Phase 1 |
| Completed | Cough Reduction in IPF With Nalbuphine ER NCT05964335 | Trevi Therapeutics | Phase 2 |
| Recruiting | Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF) NCT06230822 | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Phase 1 |
| Recruiting | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) NCT05571059 | Cumberland Pharmaceuticals | Phase 2 |
| Recruiting | A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volun NCT06267183 | Shanghai Synvida Biotechnology Co.,Ltd. | EARLY_Phase 1 |
| Completed | A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosi NCT06081621 | Regend Therapeutics | Phase 2 |
| Active Not Recruiting | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) NCT06132256 | Syndax Pharmaceuticals | Phase 2 |
| Recruiting | Validation of the C-mo System - Cough Monitoring NCT05989698 | Cough Monitoring Medical Solutions | N/A |
| Terminated | Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibr NCT06097260 | Pliant Therapeutics, Inc. | Phase 2 |
| Unknown | A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis NCT06102083 | Beijing Tide Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Londrina Activities of Daily Living Protocol in Idiopathic Pulmonary Fibrosis Patients NCT06049004 | Izmir Katip Celebi University | — |
| Completed | Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis NCT05976217 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Not Yet Recruiting | Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmon NCT05755308 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmo NCT06003426 | Bristol-Myers Squibb | Phase 3 |
| Completed | The First-in-human Study of SRN-001 in Healthy Participants NCT05984992 | siRNAgen Therapeutics Inc. | Phase 1 |
| Completed | The Assessment of Nutritional Status of Patients With IPF NCT06563011 | İrem Çağla Özel | N/A |
| Withdrawn | A Study to Investigate Leramistat in Patients With IPF NCT05951296 | Modern Biosciences Ltd | Phase 2 |
| Completed | Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy S NCT06589921 | Overseas Pharmaceuticals, Ltd. | Phase 1 |
| Completed | Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients NCT05195918 | Hal Chapman | Phase 1 |
| Completed | The Effect of N115 on Coughing in IPF Patients NCT06037408 | Cellular Sciences, inc. | Phase 3 |
| Unknown | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Heal NCT05912049 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients NCT05954988 | Rein Therapeutics | Phase 1 |
| Recruiting | SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) NCT06125327 | Guangzhou JOYO Pharma Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis NCT05842681 | Assiut University | N/A |
| Terminated | A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis a NCT05785624 | Genentech, Inc. | Phase 2 |
| Completed | Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients NCT05870956 | Boehringer Ingelheim | — |
| Completed | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis NCT05671835 | Tvardi Therapeutics, Incorporated | Phase 2 |
| Completed | A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects NCT05817240 | Endeavor Biomedicines, Inc. | Phase 1 |
| Completed | Dose Reduction and Discontinuation With Anti-Fibrotic Medications NCT05779007 | Boehringer Ingelheim | — |
| Completed | To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF NCT05483907 | Bridge Biotherapeutics, Inc. | Phase 2 |
| Completed | Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis NCT05722964 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in NCT05331729 | Centre Hospitalier Universitaire Dijon | Phase 1 |
| Unknown | Respiratory Rate Validation Study - HiCardi+ Wearable Patch Device, Mezoo Co., Ltd. NCT05863091 | Yonsei University | N/A |
| Recruiting | Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases NCT06189820 | Erasme University Hospital | Phase 2 |
| Active Not Recruiting | Atezolizumab for Idiopathic Pulmonary Fibrosis NCT05515627 | Cedars-Sinai Medical Center | Phase 1 |
| Recruiting | End-expiratory Trans-pulmonary Pressure Guided PEEP Titration in Patients With Pulmonary Fibrosis and UIP Patt NCT05098717 | University of Modena and Reggio Emilia | — |
| Completed | Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis NCT05537025 | Arrowhead Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients NCT05513950 | Chiesi Farmaceutici S.p.A. | Phase 1 |
| Completed | Effect of Intrapulmonary Percussion Ventilation on Deposition of Inhaled Aerosols in Idiopathic Pulmonary Fibr NCT05366387 | University Hospital, Tours | N/A |
| Terminated | To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF NCT05497284 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopat NCT05468502 | Shanghai Life Science & Technology | Phase 1 |
| Completed | A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IP NCT05321069 | Boehringer Ingelheim | Phase 3 |
| Completed | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibro NCT05255991 | United Therapeutics | Phase 3 |
| Enrolling By Invitation | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease NCT04905693 | United Therapeutics | Phase 3 |
| Completed | Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects NCT06135363 | Guangzhou JOYO Pharma Co., Ltd | Phase 1 |
| Unknown | Comparison of the 1-min Sit-to-Stand Test to the 6-minute Walk Test in the Respiratory Functional Assessment o NCT05449431 | Fondation Hôpital Saint-Joseph | N/A |
| Completed | Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbrie NCT05428150 | Excalibur Pharmaceuticals, Inc. | Phase 1 |
| Completed | Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis NCT05185089 | Nerre Therapeutics Ltd. | Phase 2 |
| Recruiting | Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF NCT05389215 | Daewoong Pharmaceutical Co. LTD. | Phase 2 |
| Active Not Recruiting | LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) NCT05321420 | PureTech | Phase 2 |
| Active Not Recruiting | Xenon MRI and Progressive ILD NCT05241275 | Duke University | Phase 2 |
| Completed | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) NCT05621252 | Pliant Therapeutics, Inc. | Phase 2 |
| Recruiting | Pulmonary Fibrosis Foundation Community Registry NCT05382572 | Pulmonary Fibrosis Foundation | — |
| Recruiting | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF NCT05016817 | The Foundation for Orthopaedics and Regenerative Medicine | Phase 1 |
| Unknown | A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis NCT05424887 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 |
| Completed | First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects NCT05427253 | Vicore Pharma AB | Phase 1 |
| Recruiting | Effects of Pulmonary Diseases and Their Treatment on Cardiac Function NCT05042219 | Ayham Daher | — |
| Unknown | RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) NCT05373914 | Blade Therapeutics | Phase 2 |
| Withdrawn | 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study NCT04677426 | University of Kansas Medical Center | Phase 2 |
| Recruiting | Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). NCT05052229 | Dr. Denis O'Donnell | EARLY_Phase 1 |
| Completed | Palliative Care Planner (PCplanner) NCT05095363 | Duke University | N/A |
| Completed | A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects NCT05154240 | InSilico Medicine Hong Kong Limited | Phase 1 |
| Completed | Effects of Home-based Inspiratory Muscle Training in Patients With IPF NCT05353556 | Dokuz Eylul University | N/A |
| Completed | Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis NCT05130970 | CSL Behring | Phase 2 |
| Terminated | A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic P NCT05032066 | Amgen | Phase 2 |
| Withdrawn | Development of Airway Absorption Sampling Methods NCT04494334 | Imperial College London | — |
| Completed | Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses NCT05134727 | AstraZeneca | Phase 1 |
| Completed | A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 NCT05022771 | Pulmongene Ltd. | Phase 1 |
| Recruiting | Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland NCT06702228 | Royal College of Surgeons, Ireland | — |
| Completed | A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 NCT04540770 | HuniLife Biotechnology, Inc. | Phase 1 |
| Terminated | A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Parti NCT04594707 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) NCT04968574 | Endeavor Biomedicines, Inc. | Phase 2 |
| Completed | Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients NCT05022784 | Boehringer Ingelheim | — |
| Completed | A Trial of SHR - 1906 in Healthy Subjects NCT04986540 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | Interstitial Lung Disease Research Unit Biobank NCT05392881 | University of Kansas Medical Center | — |
| Completed | To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers NCT04888715 | Daewoong Pharmaceutical Co. LTD. | Phase 1 |
| Completed | Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001 NCT05657184 | Regend Therapeutics | Phase 1 |
| Completed | To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers NCT04888728 | Daewoong Pharmaceutical Co. LTD. | Phase 1 |
| Unknown | Phase ll Study of HEC585 in Patients With IPF NCT05060822 | Sunshine Lake Pharma Co., Ltd. | Phase 2 |
| Completed | To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers NCT05383131 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Recruiting | Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole NCT04965298 | Norfolk and Norwich University Hospitals NHS Foundation Trust | Phase 3 |
| Completed | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis NCT04708782 | United Therapeutics | Phase 3 |
| Completed | A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy V NCT04931147 | Redx Pharma Ltd | Phase 1 |
| Completed | IPF mHealth Exercise Study NCT04838275 | University of Washington | N/A |
| Unknown | Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis NCT04619199 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers NCT04767815 | Daewoong Pharmaceutical Co. LTD. | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participant NCT04552899 | Hoffmann-La Roche | Phase 3 |
| Suspended | Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) NCT04643769 | Orinove, Inc. | Phase 1 |
| Unknown | Longitudinal Changes in Serum KL-6 in IPF NCT04268485 | Manchester University NHS Foundation Trust | — |
| Active Not Recruiting | Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis NCT02848625 | University of Washington | N/A |
| Completed | NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With NCT04614441 | Boehringer Ingelheim | — |
| Completed | Safety and Effectiveness of Nintedanib in Korean Patients NCT04525547 | Boehringer Ingelheim | — |
| Withdrawn | Medication Adherence and Non-adherence in Adults With Rare Disease NCT04541875 | Xperiome | — |
| Completed | Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough NCT04429516 | Royal Brompton & Harefield NHS Foundation Trust | Phase 3 |
| Completed | Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial NCT04300920 | Fernando J Martinez | Phase 3 |
| Completed | Identification of Palliative Care Needs and Prognostic Factors of Survival in Tailoring Appropriate Interventi NCT06909968 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Recruiting | Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis NCT04362644 | University of Alabama at Birmingham | Phase 1 |
| Completed | Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF NCT04533022 | Vicore Pharma AB | Phase 2 |
| Completed | Reliability and Validity of iOS in IPF NCT04572971 | Royal Brompton & Harefield NHS Foundation Trust | — |
| Active Not Recruiting | Changes in iOS in IPF NCT04572958 | Royal Brompton & Harefield NHS Foundation Trust | — |
| Unknown | Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases NCT04693975 | Universidade Estadual de Londrina | — |
| Terminated | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) NCT04419558 | Kyntra Bio | Phase 3 |
| Completed | Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis NCT04312594 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Completed | GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis NCT03865927 | University of Alabama at Birmingham | Phase 2 |
| Unknown | Jin-shui Huan-xian Granule in the Treatment of IPF NCT04187690 | Henan University of Traditional Chinese Medicine | N/A |
| Active Not Recruiting | Genentech Xenon MRI Idiopathic Pulmonary Fibrosis NCT04071769 | Duke University | Phase 2 |
| Completed | Inspiratory Muscle Training in Patients With Interstitial Lung Disease NCT04481074 | Federal University of Minas Gerais | N/A |
| Completed | Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough NCT04318704 | Algernon Pharmaceuticals | Phase 2 |
| Completed | A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary F NCT04419506 | Boehringer Ingelheim | Phase 2 |
| Completed | Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female S NCT04512170 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Recruiting | Cohort of IPF Patients Experiencing an Exacerbation NCT04442711 | University Hospital, Gentofte, Copenhagen | — |
| Completed | 23andMe IPF Research Study NCT05028894 | 23andMe, Inc. | — |
| Unknown | Heart Rate Variability and Nocturnal Blood Oxygen Saturation in Patients With Idiopathic Pulmonary Fibrosis NCT06027372 | Taipei Veterans General Hospital, Taiwan | — |
| Unknown | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection NCT04326036 | Black Tie Medical, Inc. | EARLY_Phase 1 |
| Completed | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis NCT04396756 | Pliant Therapeutics, Inc. | Phase 2 |
| Terminated | A Study of Patients With Chronic Disease NCT04263727 | Target PharmaSolutions, Inc. | — |
| Completed | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ NCT04072315 | Pliant Therapeutics, Inc. | Phase 2 |
| Completed | Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD NCT04257630 | Schön Klinik Berchtesgadener Land | — |
| Unknown | Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone NCT03692481 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy) NCT03901196 | University Hospital, Grenoble | — |
| Completed | Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects NCT04233814 | Rein Therapeutics | Phase 1 |
| Withdrawn | Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF NCT04244825 | Blade Therapeutics | Phase 2 |
| Unknown | Effect of Core Stabilization Exercises and Neuromuscular Electrical Stimulation in Patients With Idiopathic Pu NCT04197791 | Istanbul University - Cerrahpasa | N/A |
| Completed | A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects NCT04720443 | The National Institutes of Pharmaceutical R&D Co. Ltd, China | Phase 1 |
| Completed | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough NCT04030026 | Trevi Therapeutics | Phase 2 |
| Completed | Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis NCT04177251 | San Gerardo Hospital | — |
| Completed | Health and Quality of Life Assessment Project for Caregivers of Idiopathic Pulmonary Fibrosis Patients NCT04031690 | Centre Hospitalier Universitaire Dijon | — |
| Terminated | Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF NCT05359965 | University of Arizona | N/A |
| Completed | Quality of Life in IPF - Patient and Physician Perceptions NCT04148157 | University of Washington | — |
| Terminated | Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects NCT03562416 | Temple University | Phase 2 |
| Completed | Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study NCT03836417 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Terminated | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosi NCT03955146 | Kyntra Bio | Phase 3 |
| Completed | ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution NCT03944928 | University Hospital, Tours | — |
| Completed | Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis NCT03898284 | University Hospital, Tours | — |
| Terminated | A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary NCT03949530 | Indalo Therapeutics, Inc. | Phase 1 |
| Completed | Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes NCT04316780 | Steward St. Elizabeth's Medical Center of Boston, Inc. | — |
| Completed | Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis NCT03890250 | Biruni University | N/A |
| Completed | High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis NCT04564664 | Parc de Salut Mar | N/A |
| Completed | Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment W NCT03710824 | Boehringer Ingelheim | — |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects NCT03830125 | Bridge Biotherapeutics, Inc. | Phase 1 |
| Completed | A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients G NCT03958071 | Boehringer Ingelheim | — |
| Unknown | Impact of Air Pollution on Chronic Respiratory Diseases NCT03813810 | Seoul National University Hospital | — |
| Active Not Recruiting | BPF Genetics of ILD Study NCT03747627 | University of Dundee | — |
| Unknown | Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden NCT04019080 | Karolinska University Hospital | — |
| Completed | FIBRotic Interstitial Lung Disease and Nocturnal OXygen NCT04586946 | Guy's and St Thomas' NHS Foundation Trust | — |
| Completed | Nutritional Assessment in Idiopathic Pulmonary Fibrosis NCT03770845 | San Gerardo Hospital | — |
| Completed | Outcome of Idiopathic Pulmonary Fibrosis With Pregnancy NCT04775277 | Sohag University | — |
| Completed | Yoga in Patients With Fibrosing Interstitial Lung Diseases NCT03979703 | Heidelberg University | N/A |
| Completed | Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis NCT03727802 | Toray Industries, Inc | Phase 1 |
| Terminated | Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary Fibrosis NCT03744598 | patientMpower Ltd. | — |
| Terminated | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (I NCT03711162 | Galapagos NV | Phase 3 |
| Terminated | Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) NCT03717012 | Boehringer Ingelheim | Phase 4 |
| Unknown | It's Not JUST Idiopathic Pulmonary Fibrosis Study NCT03670576 | University of Nottingham | — |
| Terminated | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosi NCT03733444 | Galapagos NV | Phase 3 |
| Withdrawn | Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis NCT03258801 | Dr. Christopher Lambers | — |
| Completed | Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and Metabolomi NCT03711435 | Xuzhou Traditional Chinese Medicine Hospital | — |
| Completed | Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis NCT03499275 | Royal Brompton & Harefield NHS Foundation Trust | N/A |
| Completed | A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosi NCT03725852 | Galapagos NV | Phase 2 |
| Terminated | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis NCT03573505 | Biogen | Phase 2 |
| Completed | Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study NCT03979430 | Heidelberg University | N/A |
| Enrolling By Invitation | University of Virginia Natural History Study NCT04896138 | University of Virginia | — |
| Terminated | Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF) NCT03274544 | The University of Hong Kong | N/A |
| Terminated | Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF) NCT03562247 | Vanderbilt University Medical Center | N/A |
| Completed | Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis NCT03588260 | Istanbul Medipol University Hospital | — |
| Completed | Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis NCT03567785 | KU Leuven | — |
| Completed | Homecare Integral Support Program for IPF Patients NCT05173571 | Institut d'Investigació Biomèdica de Bellvitge | N/A |
| Unknown | Idiopathic Pulmonary Fibrosis Registry China Study NCT03666234 | Dai Huaping | — |
| Completed | JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With NCT03538301 | Nitto Denko Corporation | Phase 2 |
| Completed | Toward Self-management in ILD NCT03300583 | Kingston University | — |
| Unknown | Acute Effects of Oxygen Supplementation Among IPF Patients NCT03688334 | George Papanicolaou Hospital | N/A |
| Completed | The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects NCT03502902 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Recruiting | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure NCT03500731 | Paul Szabolcs | Phase 1 / Phase 2 |
| Active Not Recruiting | Detection of Early Idiopathic Pulmonary Fibrosis NCT03457935 | Temple University | — |
| Completed | Digital Auscultation Test - IPF Data Collection NCT03503188 | Boehringer Ingelheim | Phase 4 |
| Completed | This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study NCT03422068 | Boehringer Ingelheim | Phase 1 |
| Completed | Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in H NCT03411876 | Klaus Kenn | N/A |
| Completed | Families-At-risk for Interstitial Lung Disease Study NCT03641742 | Columbia University | — |
| Unknown | Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patient NCT03360032 | University Hospitals Coventry and Warwickshire NHS Trust | — |
| Completed | PROOF-Registry New and Extended Belgium -Luxembourg NCT03732859 | Belgian Thoracic Society | — |
| Completed | Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Lif NCT03420235 | Erasmus Medical Center | N/A |
| Completed | A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) NCT02871401 | Vanderbilt University Medical Center | Phase 1 |
| Completed | A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Dise NCT03261037 | Hoffmann-La Roche | N/A |
| Terminated | Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pul NCT03287414 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis. NCT03229343 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. NCT03928847 | Hal Chapman | EARLY_Phase 1 |
| Completed | OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study NCT03386994 | Boehringer Ingelheim | — |
| Completed | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT NCT03183570 | Stanford University | EARLY_Phase 1 |
| Completed | Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated Wi NCT03281200 | Boehringer Ingelheim | — |
| Completed | Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis NCT03208933 | Hoffmann-La Roche | Phase 3 |
| Completed | Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis NCT03222648 | University Hospital Southampton NHS Foundation Trust | N/A |
| Completed | Immunopathologic Profiles and Blood Biomarkers in Patients With IPF NCT04187079 | University of Aarhus | — |
| Completed | Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis NCT03981406 | University of Minnesota | N/A |
| Terminated | Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis NCT03480451 | Medical College of Wisconsin | N/A |
| Unknown | Feasibility & Effect of a Tele-rehabilitation Program in Idiopathic Pulmonary Fibrosis (IPF) NCT03548181 | University of Aarhus | Phase 2 |
| Terminated | A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis NCT03142191 | Celgene | Phase 2 |
| Completed | Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary NCT03104322 | patientMpower Ltd. | N/A |
| Terminated | Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomogra NCT03069989 | GlaxoSmithKline | Phase 1 |
| Unknown | Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis NCT03215147 | Seoul National University Hospital | — |
| Completed | Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis NCT03326089 | Corfu General Hospital | N/A |
| Unknown | Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis NCT03171870 | Assiut University | N/A |
| Completed | An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medi NCT05784207 | Maastricht University | — |
| Completed | The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects NCT03092102 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | Idiopathic Pulmonary Fibrosis Job Exposures Study NCT03211507 | Imperial College London | — |
| Completed | Quality of Life Study in Participants With IPF Under Pirfenidone Treatment NCT03115619 | Hoffmann-La Roche | — |
| Recruiting | Controls for Respiratory Diseases NCT03120481 | Seoul National University Hospital | — |
| Completed | Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis NCT03047031 | Boehringer Ingelheim | — |
| Completed | Investigating Idiopathic Pulmonary Fibrosis in Greece NCT03074149 | Boehringer Ingelheim | — |
| Completed | Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonar NCT02745184 | Shanghai East Hospital | Phase 1 / Phase 2 |
| Completed | Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers NCT02929017 | University of Pittsburgh | N/A |
| Terminated | CleanUP IPF for the Pulmonary Trials Cooperative NCT02759120 | Weill Medical College of Cornell University | Phase 3 |
| Completed | Lung MRI in the Management of Idiopathic Pulmonary Fibrosis NCT03078426 | University Hospital, Bordeaux | N/A |
| Completed | Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand Test NCT03268915 | University Hospital, Grenoble | N/A |
| Completed | Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease NCT04803617 | Habibedurdu | — |
| Unknown | Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease NCT03560154 | Istanbul University | N/A |
| Completed | Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Ad NCT02951429 | Hoffmann-La Roche | Phase 2 |
| Terminated | Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest NCT02989168 | Global Blood Therapeutics | Phase 2 |
| Completed | Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nat NCT02818712 | Aarhus University Hospital | — |
| Active Not Recruiting | Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Id NCT05313672 | Roberto Tonelli | — |
| Unknown | The Coagulation Cascade in Idiopathic Pulmonary Fibrosis NCT02885961 | University College, London | N/A |
| Completed | Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients Wi NCT02802345 | Boehringer Ingelheim | Phase 3 |
| Completed | Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibr NCT02788474 | Boehringer Ingelheim | Phase 4 |
| Completed | Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF NCT02846324 | Global Blood Therapeutics | Phase 2 |
| Terminated | Turkish Thoracic Society Usual Interstitial Pneumonia Registry Study NCT02821039 | Turkish Thoracic Society | — |
| Completed | A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis NCT02688647 | Kadmon Corporation, LLC | Phase 2 |
| Completed | Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis NCT02739165 | Asahi Kasei Therapeutics Corporation | Phase 3 |
| Completed | Sleep Disorders in Idiopathic Pulmonary Fibrosis NCT05113654 | Wissenschaftliches Institut Bethanien e.V | — |
| Completed | A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are G NCT02606877 | Boehringer Ingelheim | Phase 4 |
| Active Not Recruiting | Pulmonary Fibrosis Biomarker Cohort - a Prospective Cohort of Incident Patients With IPF NCT02755441 | Nils Hoyer | — |
| Completed | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis NCT02503657 | MediciNova | Phase 2 |
| Active Not Recruiting | Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay NCT02772549 | Nils Hoyer | — |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects W NCT02738801 | Galapagos NV | Phase 2 |
| Completed | A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis NCT02648048 | Hoffmann-La Roche | Phase 1 |
| Completed | Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pu NCT02598193 | Hoffmann-La Roche | Phase 4 |
| Recruiting | Korean Idiopathic Pulmonary Fibrosis Registry NCT04160715 | Seoul National University Hospital | — |
| Completed | Exhaled Breath Condensate Biomarkers and Cough in IPF NCT02630940 | University of East Anglia | — |
| Completed | First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patient NCT02612051 | GlaxoSmithKline | Phase 1 |
| Recruiting | High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nint NCT02551068 | University of British Columbia | N/A |
| Completed | Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis NCT02632123 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Completed | Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis NCT02460588 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis NCT02803580 | Boehringer Ingelheim | — |
| Completed | Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF NCT02579603 | Boehringer Ingelheim | Phase 4 |
| Unknown | Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD) NCT02827734 | Universitätsmedizin Mannheim | — |
| Completed | A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) NCT02550873 | Hoffmann-La Roche | Phase 2 |
| Completed | All-Case Surveillance of Ofev in Patients With IPF in Japan NCT02607722 | Boehringer Ingelheim | — |
| Completed | A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persisten NCT02502097 | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis NCT02600689 | University of Alabama at Birmingham | N/A |
| Completed | A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic NCT02477709 | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Withdrawn | Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idi NCT02187393 | University of Colorado, Denver | — |
| Terminated | Cromolyn Detection of Silent Aspiration NCT01841307 | University of California, San Francisco | Phase 1 |
| Completed | Breath Analysis in Lung Fibrosis NCT02437448 | University of Zurich | — |
| Completed | The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Pati NCT02019641 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension As NCT02267655 | Bellerophon | Phase 1 |
| Completed | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis NCT02345070 | Sanofi | Phase 2 |
| Completed | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis NCT02478268 | Bastiaan Driehuys | Phase 1 |
| Unknown | Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male NCT02397005 | Zai Lab Pty. Ltd. | Phase 1 |